Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017, Article ID 9157370, 13 pages
https://doi.org/10.1155/2017/9157370
Review Article

MicroRNA Regulation of Glycolytic Metabolism in Glioblastoma

Children’s Brain Tumour Research Centre, Queen’s Medical Centre, D22 Medical School, School of Medicine, University of Nottingham, Nottingham NG7 2UH, UK

Correspondence should be addressed to Huda Alfardus; ku.ca.mahgnitton@aohxap

Received 5 May 2017; Accepted 22 June 2017; Published 19 July 2017

Academic Editor: Marta M. Alonso

Copyright © 2017 Huda Alfardus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Iacob and E. B. Dinca, “Current data and strategy in glioblastoma multiforme,” Journal of Medicine and Life, vol. 2, no. 4, pp. 386–393, 2009. View at Google Scholar · View at Scopus
  2. H. Zong, R. G. W. Verhaak, and P. Canolk, “The cellular origin for malignant glioma and prospects for clinical advancements,” Expert Review of Molecular Diagnostics, vol. 12, no. 4, pp. 383–394, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Google Scholar · View at Scopus
  4. H. Ohgaki and P. Kleihues, “Epidemiology and etiology of gliomas,” Acta Neuropathologica, vol. 109, no. 1, pp. 93–108, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Brodbelt, D. Greenberg, T. Winters, M. Williams, S. Vernon, and V. P. Collins, “Glioblastoma in England: 2007–2011,” European Journal of Cancer, vol. 51, no. 4, pp. 533–542, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. Q. T. Ostrom, H. Gittleman, P. Farah et al., “CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010,” Neuro-Oncology, vol. 15, supplement 2, pp. ii1–ii56, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. D. Walker, E. Alexander Jr., W. E. Hunt et al., “Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial,” Journal of Neurosurgery, vol. 49, no. 3, pp. 333–343, 1978. View at Publisher · View at Google Scholar · View at Scopus
  9. B. Tran and M. A. Rosenthal, “Survival comparison between glioblastoma multiforme and other incurable cancers,” Journal of Clinical Neuroscience, vol. 17, no. 4, pp. 417–421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. M. Koshy, J. L. Villano, T. A. Dolecek et al., “Improved survival time trends for glioblastoma using the SEER 17 population-based registries,” Journal of Neuro-Oncology, vol. 107, no. 1, pp. 207–212, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Phan, S.-C. J. Yeung, and M.-H. Lee, “Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies,” Cancer Biology & Medicine, vol. 11, no. 1, pp. 1–19, 2014. View at Publisher · View at Google Scholar
  12. D. Hanahan and R. A. Weinberg, “Hallmarks of cancer: the next generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Zhang and J.-M. Yang, “Altered energy metabolism in cancer: A unique opportunity for therapeutic intervention,” Cancer Biology and Therapy, vol. 14, no. 2, pp. 81–89, 2013. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Ganapathy-Kanniappan and J. F. Geschwind, “Tumor glycolysis as a target for cancer therapy: progress and prospects,” Molecular Cancer, vol. 12, no. 1, article 152, 2013. View at Publisher · View at Google Scholar
  15. P. S. Ward and C. B. Thompson, “Metabolic reprogramming: a cancer hallmark even warburg did not anticipate,” Cancer Cell, vol. 21, no. 3, pp. 297–308, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Oudard, F. Arvelo, L. Miccoli et al., “High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss,” British Journal of Cancer, vol. 74, no. 6, pp. 839–845, 1996. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Tabatabaei, P. Bergström, R. Henriksson, and A. T. Bergenheim, “Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy,” Journal of Neuro-Oncology, vol. 90, no. 1, pp. 35–39, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. O. Warburg, “On the origin of cancer cells,” Science, vol. 123, no. 3191, pp. 309–314, 1956. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. DeBerardinis, “Is cancer a disease of abnormal cellular metabolism? New angles on an old idea,” Genetics in Medicine, vol. 10, no. 11, pp. 767–777, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Chekulaeva and W. Filipowicz, “Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells,” Current Opinion in Cell Biology, vol. 21, no. 3, pp. 452–460, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. Cancer Genome Atlas Research Network, “Comprehensive genomic characterization defines human glioblastoma genes and core pathways,” Nature, vol. 455, no. 7216, pp. 1061–1068, 2008. View at Google Scholar
  22. M. A. Lemmon and J. Schlessinger, “Cell signaling by receptor tyrosine kinases,” Cell, vol. 141, no. 7, pp. 1117–1134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. H. W. Yang, M.-G. Shin, S. Lee et al., “Cooperative activation of PI3K by Ras and Rho family small GTPases,” Molecular Cell, vol. 47, no. 2, pp. 281–290, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Arcaro, M. J. Zvelebil, C. Wallasch, A. Ullrich, M. D. Waterfield, and J. Domin, “Class II phosphoinositide 3-kinases are downstream targets of activated polypeptide growth factor receptors,” Molecular and Cellular Biology, vol. 20, no. 11, pp. 3817–3830, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. R. Dhand, I. Hiles, G. Panayotou et al., “PI 3-kinase is a dual specificity enzyme: Autoregulation by an intrinsic protein-serine kinase activity,” EMBO Journal, vol. 13, no. 3, pp. 522–533, 1994. View at Google Scholar · View at Scopus
  26. T. Maehama and J. E. Dixon, “The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate,” The Journal of Biological Chemistry, vol. 273, no. 22, pp. 13375–13378, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Frech, M. Andjelkovic, E. Ingley, K. K. Reddy, J. R. Falck, and B. A. Hemmings, “High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity,” Journal of Biological Chemistry, vol. 272, no. 13, pp. 8474–8481, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. T. F. Franke, S. I. Yang, T. O. Chan et al., “The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase,” Cell, vol. 81, no. 5, pp. 727–736, 1995. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Yang, D. S. Murashige, S. J. Humphrey, and D. E. James, “A positive feedback loop between Akt and mTORC2 via SIN1 phosphorylation,” Cell Reports, vol. 12, no. 6, pp. 937–943, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. B. D. Manning, A. R. Tee, M. N. Logsdon, J. Blenis, and L. C. Cantley, “Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway,” Molecular Cell, vol. 10, no. 1, pp. 151–162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Inoki, Y. Li, T. Zhu, J. Wu, and K.-L. Guan, “TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling,” Nature Cell Biology, vol. 4, no. 9, pp. 648–657, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. B. D. Manning and L. C. Cantley, “Rheb fills a GAP between TSC and TOR,” Trends in Biochemical Sciences, vol. 28, no. 11, pp. 573–576, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. D. G. Hardie and S. A. Hawley, “AMP-activated protein kinase: The energy charge hypothesis revisited,” BioEssays, vol. 23, no. 12, pp. 1112–1119, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Kefas, L. Comeau, N. Erdle, E. Montgomery, S. Amos, and B. Purow, “Pyruvate kinase M2 is a target of the tumorsuppressive microRNA-326 and regulates the survival of glioma cells,” Neuro-Oncology, vol. 12, no. 11, pp. 1102–1112, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Inoki, T. Zhu, and K.-L. Guan, “TSC2 mediates cellular energy response to control cell growth and survival,” Cell, vol. 115, no. 5, pp. 577–590, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. D. M. Gwinn, D. B. Shackelford, D. F. Egan et al., “AMPK phosphorylation of raptor mediates a metabolic checkpoint,” Molecular Cell, vol. 30, no. 2, pp. 214–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. K. Masui, K. Tanaka, D. Akhavan et al., “MTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc,” Cell Metabolism, vol. 18, no. 5, pp. 726–739, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. D. M. Miller, S. D. Thomas, A. Islam, D. Muench, and K. Sedoris, “c-Myc and cancer metabolism,” Clinical Cancer Research, vol. 18, no. 20, pp. 5546–5553, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. C. V. Dang, “MYC, metabolism, cell growth, and tumorigenesis,” Cold Spring Harbor Perspectives in Medicine, vol. 3, no. 8, Article ID a014217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. H. L. Wieman, J. A. Wofford, and J. C. Rathmell, “Cytokine stimulation promotes glucose uptake via phosphatidylinositol-3 kinase/Akt regulation of Glut1 activity and trafficking,” Molecular Biology of the Cell, vol. 18, no. 4, pp. 1437–1446, 2007. View at Publisher · View at Google Scholar
  41. R. J. Boado, K. L. Black, and W. M. Pardridge, “Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors,” Molecular Brain Research, vol. 27, no. 1, pp. 51–57, 1994. View at Publisher · View at Google Scholar · View at Scopus
  42. C. L. Neary and J. G. Pastorino, “Akt inhibition promotes hexokinase 2 redistribution and glucose uptake in cancer cells,” Journal of Cellular Physiology, vol. 228, no. 9, pp. 1943–1948, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. R. L. Elstrom, D. E. Bauer, M. Buzzai et al., “Akt stimulates aerobic glycolysis in cancer cells,” Cancer Research, vol. 64, no. 11, pp. 3892–3899, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. N. K. Kloosterhof, L. B. Bralten, H. J. Dubbink, P. J. French, and M. J. van den Bent, “Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?” The Lancet Oncology, vol. 12, no. 1, pp. 83–91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Jiao, P. J. Killela, Z. J. Reitman et al., “Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas,” Oncotarget, vol. 3, no. 7, pp. 709–722, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Dang, D. W. White, S. Gross et al., “Cancer-associated IDH1 mutations produce 2-hydroxyglutarate,” Nature, vol. 462, no. 7274, pp. 739–744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. W. Xu, H. Yang, Y. Liu et al., “Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases,” Cancer Cell, vol. 19, no. 1, pp. 17–30, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. T. Shinawi, V. K. Hill, D. Krex et al., “DNA methylation profiles of long- and short-term glioblastoma survivors,” Epigenetics, vol. 8, no. 2, pp. 149–156, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. H. Noushmehr, D. J. Weisenberger, K. Diefes et al., “Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma,” Cancer Cell, vol. 17, no. 5, pp. 510–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. B. Verbeek, T. D. Southgate, D. E. Gilham, and G. P. Margison, “O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy,” British Medical Bulletin, vol. 85, no. 1, pp. 17–33, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. A. E. Pegg, “Mammalian 06-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents,” Cancer Research, vol. 50, no. 19, pp. 6119–6129, 1990. View at Google Scholar · View at Scopus
  52. J. Dunn, A. Baborie, F. Alam et al., “Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy,” British Journal of Cancer, vol. 101, no. 1, pp. 124–131, 2009. View at Publisher · View at Google Scholar
  53. M. E. Hegi, A.-C. Diserens, T. Gorlia et al., “MGMT gene silencing and benefit from temozolomide in glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 997–1003, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. W. Wick, M. Weller, M. van den Bent et al., “MGMT testing—the challenges for biomarker-based glioma treatment,” Nature Reviews Neurology, vol. 10, no. 7, pp. 372–385, 2014. View at Publisher · View at Google Scholar
  55. N. Thon, S. Kreth, and F.-W. Kreth, “Personalized treatment strategies in glioblastoma: MGMT promoter methylation status,” OncoTargets and Therapy, vol. 6, pp. 1363–1372, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Reifenberger, B. Hentschel, J. Felsberg et al., “Predictive impact of MGMT promoter methylation in glioblastoma of the elderly,” International Journal of Cancer, vol. 131, no. 6, pp. 1342–1350, 2012. View at Publisher · View at Google Scholar · View at Scopus
  57. Z. J. Reitman and H. Yan, “Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism,” Journal of the National Cancer Institute, vol. 102, no. 13, pp. 932–941, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. D. A. N. Mustafa, S. M. Swagemakers, L. Buise, P. J. van der Spek, and J. M. Kros, “Metabolic alterations due to IDH1 mutation in glioma: Opening for therapeutic opportunities?” Acta Neuropathologica Communications, vol. 2, no. 1, article no. 6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Chesnelong, M. M. Chaumeil, M. D. Blough et al., “Lactate dehydrogenase A silencing in IDH mutant gliomas,” Neuro-Oncology, vol. 16, no. 5, pp. 686–695, 2014. View at Publisher · View at Google Scholar · View at Scopus
  60. C. V. Dang, “Role of aerobic glycolysis in genetically engineered mouse models of cancer,” BMC Biology, vol. 11, article no. 3, 2013. View at Publisher · View at Google Scholar · View at Scopus
  61. J. L. Izquierdo-Garcia, P. Viswanath, P. Eriksson et al., “Metabolic reprogramming in mutant IDH1 glioma cells,” PLoS ONE, vol. 10, no. 2, Article ID e0118781, 2015. View at Publisher · View at Google Scholar · View at Scopus
  62. J. L. Izquierdo-Garcia, P. Viswanath, P. Eriksson et al., “IDH1 mutation induces reprogramming of pyruvate metabolism,” Cancer Research, vol. 75, no. 15, pp. 2999–3009, 2015. View at Publisher · View at Google Scholar · View at Scopus
  63. P. Birner, S. Pusch, C. Christov et al., “Mutant IDH1 inhibits PI3K/Akt signaling in human glioma,” Cancer, vol. 120, no. 16, pp. 2440–2447, 2014. View at Publisher · View at Google Scholar · View at Scopus
  64. S. K. Hermansen and B. W. Kristensen, “MicroRNA biomarkers in glioblastoma,” Journal of Neuro-Oncology, vol. 114, no. 1, pp. 13–23, 2013. View at Publisher · View at Google Scholar · View at Scopus
  65. A. Shea, V. Harish, Z. Afzal et al., “MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics,” Cancer Medicine, vol. 5, no. 8, pp. 1917–1946, 2016. View at Publisher · View at Google Scholar · View at Scopus
  66. D.-W. Dai, Q. Lu, L.-X. Wang et al., “Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM,” BMC Cancer, vol. 13, article no. 478, 2013. View at Publisher · View at Google Scholar · View at Scopus
  67. S. Zhao, H. Liu, Y. Liu et al., “MiR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells,” Cancer Letters, vol. 333, no. 2, pp. 253–260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. W. Luan, Y. Wang, X. Chen et al., “PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop,” Oncotarget, vol. 6, no. 15, pp. 13006–13018, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Yang, R. Zhang, X. Chen et al., “MiR-106a inhibits glioma cell growth by targeting E2F1 independent of p53 status,” Journal of Molecular Medicine, vol. 89, no. 10, pp. 1037–1050, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Zhao, G. Yang, Y. Mu et al., “MiR-106a is an independent prognostic marker in patients with glioblastoma,” Neuro-Oncology, vol. 15, no. 6, pp. 707–717, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. Liu, Y.-M. Li, R.-F. Tian et al., “The expression and significance of HIF-1α and GLUT-3 in glioma,” Brain Research, vol. 1304, pp. 149–154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Wang, Z.-M. Shi, C.-F. Jiang et al., “MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma,” Oncotarget, vol. 5, no. 14, pp. 5416–5427, 2014. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Wolf, S. Agnihotri, J. Micallef et al., “Hexokinase 2 is a key mediator of Aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme,” The Journal of Experimental Medicine, vol. 208, no. 2, pp. 313–326, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Noguchi, H. Inoue, and T. Tanaka, “The M1- and M2-type isozymes of rat pyruvate kinase are produced from the same gene by alternative RNA splicing,” The Journal of Biological Chemistry, vol. 261, no. 29, pp. 13807–13812, 1986. View at Google Scholar
  75. H. R. Christofk, M. G. V. Heiden, M. H. Harris et al., “The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth,” Nature, vol. 452, no. 7184, pp. 230–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Michlewski and J. F. Cáceres, “Antagonistic role of hnRNP A1 and KSRP in the regulation of let-7a biogenesis,” Nature Structural and Molecular Biology, vol. 17, no. 8, pp. 1011–1018, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. M. Chen, J. Zhang, and J. L. Manley, “Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA,” Cancer Research, vol. 70, no. 22, pp. 8977–8980, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. I. Babic, E. S. Anderson, K. Tanaka et al., “EGFR mutation-induced alternative splicing of max contributes to growth of glycolytic tumors in brain cancer,” Cell Metabolism, vol. 17, no. 6, pp. 1000–1008, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. T. P. Mäkelä, P. J. Koskinen, I. Västrik, and K. Alitalo, “Alternative forms of Max as enhancers or suppressors of myc-ras cotransformation,” Science, vol. 256, no. 5055, pp. 373–377, 1992. View at Publisher · View at Google Scholar · View at Scopus
  80. C. J. David, M. Chen, M. Assanah, P. Canoll, and J. L. Manley, “HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer,” Nature, vol. 463, no. 7279, pp. 364–368, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. B. Kefas, L. Comeau, D. H. Floyd et al., “The neuronal microRNA miR-326 acts in a feedback loop with Notch and has therapeutic potential against brain tumors,” Journal of Neuroscience, vol. 29, no. 48, pp. 15161–15168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Zhang, X. Pan, G. P. Cobb, and T. A. Anderson, “microRNAs as oncogenes and tumor suppressors,” Developmental Biology, vol. 302, no. 1, pp. 1–12, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. D. Wang, C. Qiu, H. Zhang, J. Wang, Q. Cui, and Y. Yin, “Human MicroRNA oncogenes and tumor suppressors show significantly different biological patterns: from functions to targets,” PLoS ONE, vol. 5, no. 9, Article ID e13067, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. M. Rivera-Díaz, M. A. Miranda-Román, D. Soto et al., “MicroRNA-27a distinguishes glioblastoma multiforme from diffuse and anaplastic astrocytomas and has prognostic value,” American Journal of Cancer Research, vol. 5, no. 1, pp. 201–218, 2015. View at Google Scholar
  85. N. M. Teplyuk, E. J. Uhlmann, G. Gabriely et al., “Therapeutic potential of targeting microRNA-10b in established intracranial glioblastoma: First steps toward the clinic,” EMBO Molecular Medicine, vol. 8, no. 3, pp. 268–287, 2016. View at Publisher · View at Google Scholar · View at Scopus
  86. L. Chen, J. Zhang, Y. Feng et al., “MiR-410 regulates MET to influence the proliferation and invasion of glioma,” International Journal of Biochemistry and Cell Biology, vol. 44, no. 11, pp. 1711–1717, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. F. Lan, H. Yu, M. Hu, T. Xia, and X. Yue, “MiR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met,” Journal of Neurochemistry, vol. 135, no. 2, pp. 274–286, 2015. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Silber, A. Jacobsen, T. Ozawa et al., “miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis,” PLoS ONE, vol. 7, no. 3, Article ID e33844, 2012. View at Publisher · View at Google Scholar · View at Scopus
  89. S. S. Rathod, S. B. Rani, M. Khan, D. Muzumdar, and A. Shiras, “Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways,” FEBS Open Bio, vol. 4, pp. 485–495, 2014. View at Publisher · View at Google Scholar
  90. S. Luan, L. Sun, and F. Huang, “MicroRNA-34a: a novel tumor suppressor in p53-mutant glioma cell line U251,” Archives of Medical Research, vol. 41, no. 2, pp. 67–74, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. Y. Li, F. Guessous, Z. Ying et al., “MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes,” Cancer Research, vol. 69, no. 19, pp. 7569–7576, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. H. Kantarjian, C. Sawyers, A. Hochhaus et al., “Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia,” The New England Journal of Medicine, vol. 346, no. 9, pp. 645–652, 2002. View at Publisher · View at Google Scholar · View at Scopus
  93. C. Haberler, E. Gelpi, C. Marosi et al., “Immunohistochemical analysis of platelet-derived growth factor receptor-α, -β, c-kit, c-abl, and arg proteins in glioblastoma: Possible implications for patient selection for imatinib mesylate therapy,” Journal of Neuro-Oncology, vol. 76, no. 2, pp. 105–109, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. T. Papagiannakopoulos, D. Friedmann-Morvinski, P. Neveu et al., “Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases,” Oncogene, vol. 31, no. 15, pp. 1884–1895, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. S. A. Ciafrè, S. Galardi, A. Mangiola et al., “Extensive modulation of a set of microRNAs in primary glioblastoma,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1351–1358, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. C. Shang, Y. Hong, Y. Guo, Y.-H. Liu, and Y.-X. Xue, “MiR-128 regulates the apoptosis and proliferation of glioma cells by targeting RhoE,” Oncology Letters, vol. 11, no. 1, pp. 904–908, 2016. View at Publisher · View at Google Scholar · View at Scopus
  97. J. Godlewski, M. O. Nowicki, A. Bronisz et al., “Targeting of the Bmi-1 oncogene/stem cell renewal factor by MicroRNA-128 inhibits glioma proliferation and self-renewal,” Cancer Research, vol. 68, no. 22, pp. 9125–9130, 2008. View at Publisher · View at Google Scholar · View at Scopus
  98. Y. Zhang, T. Chao, R. Li et al., “MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a,” Journal of Molecular Medicine, vol. 87, no. 1, pp. 43–51, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. A. M. Krichevsky, K. S. King, C. P. Donahue, K. Khrapko, and K. S. Kosik, “A microRNA array reveals extensive regulation of microRNAs during brain development,” RNA, vol. 9, no. 10, pp. 1274–1281, 2003. View at Google Scholar
  100. S. A. M. Rao, V. Santosh, and K. Somasundaram, “Genome-wide expression profiling identifies deregulated miRNAs in malignant astrocytoma,” Modern Pathology, vol. 23, no. 10, pp. 1404–1417, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. S. A. M. Rao, A. Arimappamagan, P. Pandey et al., “miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma,” PLoS ONE, vol. 8, no. 5, Article ID e63164, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. C.-P. Kung and N. Raab-Traub, “Epstein-Barr virus latent membrane protein 1 induces expression of the epidermal growth factor receptor through effects on Bcl-3 and STAT3,” Journal of Virology, vol. 82, no. 11, pp. 5486–5493, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. M. Rehmsmeier, P. Steffen, M. Höchsmann, and R. Giegerich, “Fast and effective prediction of microRNA/target duplexes,” RNA, vol. 10, no. 10, pp. 1507–1517, 2004. View at Publisher · View at Google Scholar · View at Scopus
  104. D. Löffler, K. Brocke-Heidrich, G. Pfeifer et al., “Interleukin-6-dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer,” Blood, vol. 110, no. 4, pp. 1330–1333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  105. X. Zhou, Y. Ren, L. Moore et al., “Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status,” Laboratory Investigation, vol. 90, no. 2, pp. 144–155, 2010. View at Publisher · View at Google Scholar · View at Scopus
  106. R. Lakomy, J. Sana, S. Hankeova et al., “MiR-195, miR-196b, miR-181c, miR-21 expression levels and O-6-methylguanine-DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients,” Cancer Science, vol. 102, no. 12, pp. 2186–2190, 2011. View at Publisher · View at Google Scholar · View at Scopus
  107. Y. Ren, X. Zhou, M. Mei et al., “MicroRNA-21 inhibitor sensitizes human glioblastoma cells U251 (PTEN-mutant) and LN229 (PTEN-wild type) to taxol,” BMC Cancer, vol. 10, article no. 27, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. H.-J. Kwak, Y.-J. Kim, K.-R. Chun et al., “Downregulation of Spry2 by miR-21 triggers malignancy in human gliomas,” Oncogene, vol. 30, no. 21, pp. 2433–2442, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. F. Zhi, X. Chen, S. Wang et al., “The use of hsa-miR-21, hsa-miR-181b and hsa-miR-106a as prognostic indicators of astrocytoma,” European Journal of Cancer, vol. 46, no. 9, pp. 1640–1649, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. G. Gabriely, T. Wurdinger, S. Kesari et al., “MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators,” Molecular and Cellular Biology, vol. 28, no. 17, pp. 5369–5380, 2008. View at Publisher · View at Google Scholar · View at Scopus
  111. J. A. Chan, A. M. Krichevsky, and K. S. Kosik, “MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells,” Cancer Research, vol. 65, no. 14, pp. 6029–6033, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. E. Lages, A. Guttin, M. E. Atifi et al., “MicroRNA and target protein patterns reveal physiopathological features of glioma subtypes,” PLoS ONE, vol. 6, no. 5, Article ID e20600, 2011. View at Publisher · View at Google Scholar · View at Scopus
  113. B. Malzkorn, M. Wolter, F. Liesenberg et al., “Identification and functional characterization of microRNAs involved in the malignant progression of gliomas,” Brain Pathology, vol. 20, no. 3, pp. 539–550, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. T. Papagiannakopoulos, A. Shapiro, and K. S. Kosik, “MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells,” Cancer Research, vol. 68, no. 19, pp. 8164–8172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  115. X. Zhou, J. Zhang, Q. Jia et al., “Reduction of miR-21 induces glioma cell apoptosis via activating caspase 9 and 3,” Oncology Reports, vol. 24, no. 1, pp. 195–201, 2010. View at Publisher · View at Google Scholar
  116. L. Shi, J. Chen, J. Yang, T. Pan, S. Zhang, and Z. Wang, “MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity,” Brain Research, vol. 1352, pp. 255–264, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Dong, L. Luo, S. Hong et al., “Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma,” BMC Systems Biology, vol. 4, article no. 163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  118. M. F. Corsten, R. Miranda, R. Kasmieh, A. M. Krichevsky, R. Weissleder, and K. Shah, “MicroRNA-21 knockdown disrupts glioma growth In vivo and displays synergistic cytotoxicity with neural precursor cell-delivered S-TRAIL in human gliomas,” Cancer Research, vol. 67, no. 19, pp. 8994–9000, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. B. Kefas, J. Godlewski, L. Comeau et al., “microRNA-7 inhibits the epidermal growth factor receptor and the akt pathway and is down-regulated in glioblastoma,” Cancer Research, vol. 68, no. 10, pp. 3566–3572, 2008. View at Publisher · View at Google Scholar · View at Scopus
  120. R. J. Webster, K. M. Giles, K. J. Price, P. M. Zhang, J. S. Mattick, and P. J. Leedman, “Regulation of epidermal growth factor receptor signaling in human cancer cells by MicroRNA-7,” The Journal of Biological Chemistry, vol. 284, no. 9, pp. 5731–5741, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. Z. Liu, Z. Jiang, J. Huang et al., “miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways,” International Journal of Oncology, vol. 44, no. 5, pp. 1571–1580, 2014. View at Publisher · View at Google Scholar · View at Scopus
  122. X. Tan, S. Wang, B. Yang et al., “The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells,” PLoS ONE, vol. 7, no. 11, Article ID e49570, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. Z. Wu, L. Wang, G. Li et al., “Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma,” Molecular and Cellular Biochemistry, vol. 384, no. 1-2, pp. 263–268, 2013. View at Publisher · View at Google Scholar · View at Scopus
  124. D. Huang, S. Qiu, R. Ge et al., “miR-340 suppresses glioblastoma multiforme,” Oncotarget, vol. 6, no. 11, pp. 9257–9270, 2015. View at Publisher · View at Google Scholar · View at Scopus
  125. D. Fiore, E. Donnarumma, G. Roscigno et al., “miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS,” Oncotarget, vol. 7, no. 15, pp. 19531–19547, 2016. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Kim, W. Huang, X. Jiang, B. Pennicooke, P. J. Park, and M. D. Johnson, “Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 5, pp. 2183–2188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  127. Y. Zhang, J. Kim, A. C. Mueller et al., “Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma,” Cell Death and Differentiation, vol. 21, no. 5, pp. 720–734, 2014. View at Publisher · View at Google Scholar · View at Scopus
  128. P. Guo, Q. Nie, J. Lan, J. Ge, Y. Qiu, and Q. Mao, “C-Myc negatively controls the tumor suppressor PTEN by upregulating miR-26a in glioblastoma multiforme cells,” Biochemical and Biophysical Research Communications, vol. 441, no. 1, pp. 186–190, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. J. T. Huse, C. Brennan, D. Hambardzumyan et al., “The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo,” Genes and Development, vol. 23, no. 11, pp. 1327–1337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  130. X. Xia, Y. Li, W. Wang et al., “MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway,” Molecular Cancer, vol. 14, no. 1, article no. 154, 2015. View at Publisher · View at Google Scholar · View at Scopus
  131. X.-T. Li, H.-Z. Wang, Z.-W. Wu et al., “miR-494-3p regulates cellular proliferation, invasion, migration, and apoptosis by PTEN/AKT signaling in human glioblastoma cells,” Cellular and Molecular Neurobiology, vol. 35, no. 5, pp. 679–687, 2015. View at Publisher · View at Google Scholar · View at Scopus
  132. S. Liu, J. Sun, and Q. Lan, “TGF-β-induced miR10a/b expression promotes human glioma cell migration by targeting PTEN,” Molecular Medicine Reports, vol. 8, no. 6, pp. 1741–1746, 2013. View at Publisher · View at Google Scholar · View at Scopus
  133. F. Guessous, M. Alvarado-Velez, L. Marcinkiewicz et al., “Oncogenic effects of miR-10b in glioblastoma stem cells,” Journal of Neuro-Oncology, vol. 112, no. 2, pp. 153–163, 2013. View at Publisher · View at Google Scholar · View at Scopus
  134. A. Conti, M. Aguennouz, D. La Torre et al., “miR-21 and 221 upregulation and miR-181b downregulation in human grade II-IV astrocytic tumors,” Journal of Neuro-Oncology, vol. 93, no. 3, pp. 325–332, 2009. View at Publisher · View at Google Scholar · View at Scopus
  135. J. Cai, J. Zhao, N. Zhang et al., “MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma,” Journal of Biological Chemistry, vol. 290, no. 41, pp. 24678–24688, 2015. View at Publisher · View at Google Scholar · View at Scopus
  136. J. Godlewski, M. O. Nowicki, A. Bronisz et al., “MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells,” Molecular Cell, vol. 37, no. 5, pp. 620–632, 2010. View at Publisher · View at Google Scholar · View at Scopus
  137. Z. Luo, M. Zang, and W. Guo, “AMPK as a metabolic tumor suppressor: control of metabolism and cell growth,” Future Oncology, vol. 6, no. 3, pp. 457–470, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. K. I. Ansari, D. Ogawa, A. K. Rooj et al., “Glucose-based regulation of miR-451/AMPK signaling depends on the OCT1 transcription factor,” Cell Reports, vol. 11, no. 6, pp. 902–909, 2015. View at Publisher · View at Google Scholar · View at Scopus
  139. L. Shen, C. Sun, Y. Li et al., “MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway,” Tumor Biology, vol. 36, no. 9, pp. 6929–6938, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. R. C. Hresko and M. Mueckler, “mTOR·RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes,” The Journal of Biological Chemistry, vol. 280, no. 49, pp. 40406–40416, 2005. View at Publisher · View at Google Scholar · View at Scopus
  141. K. Tateishi, A. J. Iafrate, Q. Ho et al., “Myc-Driven glycolysis is a therapeutic target in glioblastoma,” Clinical Cancer Research, vol. 22, no. 17, pp. 4452–4465, 2016. View at Publisher · View at Google Scholar · View at Scopus
  142. N. Ling, J. Gu, Z. Lei et al., “MicroRNA-155 regulates cell proliferation and invasion by targeting FOXO3a in glioma,” Oncology Reports, vol. 30, no. 5, pp. 2111–2118, 2013. View at Publisher · View at Google Scholar · View at Scopus
  143. P. I. D'Urso, O. F. D'Urso, C. Storelli et al., “miR-155 is up-regulated in primary and secondary glioblastoma and promotes tumour growth by inhibiting GABA receptors,” International Journal of Oncology, vol. 41, no. 1, pp. 228–234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. J. Sun, H. Shi, N. Lai, K. Liao, S. Zhang, and X. Lu, “Overexpression of microRNA-155 predicts poor prognosis in glioma patients,” Medical Oncology, vol. 31, no. 4, article no. 911, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. M. Liu, J. Gao, Q. Huang, Y. Jin, and Z. Wei, “Downregulating microRNA-144 mediates a metabolic shift in lung cancer cells by regulating GLUT1 expression,” Oncology Letters, vol. 11, no. 6, pp. 3772–3776, 2016. View at Publisher · View at Google Scholar · View at Scopus
  146. R. Fang, T. Xiao, Z. Fang et al., “MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene,” Journal of Biological Chemistry, vol. 287, no. 27, pp. 23227–23235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  147. L. H. Gregersen, A. Jacobsen, L. B. Frankel, J. Wen, A. Krogh, and A. H. Lund, “MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells,” BMC Cancer, vol. 12, pp. 232–236, 2012. View at Publisher · View at Google Scholar
  148. A. Peschiaroli, A. Giacobbe, A. Formosa et al., “MiR-143 regulates hexokinase 2 expression in cancer cells,” Oncogene, vol. 32, no. 6, pp. 797–802, 2013. View at Publisher · View at Google Scholar · View at Scopus
  149. S. Jiang, L.-F. Zhang, H.-W. Zhang et al., “A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells,” EMBO Journal, vol. 31, no. 8, pp. 1985–1998, 2012. View at Publisher · View at Google Scholar · View at Scopus
  150. S. Mattiske, R. J. Suetani, P. M. Neilsen, and D. F. Callen, “The oncogenic role of miR-155 in breast cancer,” Cancer Epidemiology, Biomarkers & Prevention, vol. 21, no. 8, pp. 1236–1243, 2012. View at Publisher · View at Google Scholar · View at Scopus
  151. J. Yang, J. Li, Y. Le, C. Zhou, S. Zhang, and Z. Gong, “PFKL/miR-128 axis regulates glycolysis by inhibiting AKT phosphorylation and predicts poor survival in lung cancer,” American Journal of Cancer Research, vol. 6, no. 2, pp. 473–485, 2016. View at Google Scholar · View at Scopus
  152. X. Xiao, X. Huang, F. Ye et al., “The MIR-34a-LDHA axis regulates glucose metabolism and tumor growth in breast cancer,” Scientific Reports, vol. 6, Article ID 21735, 2016. View at Publisher · View at Google Scholar · View at Scopus
  153. H. Peurala, D. Greco, T. Heikkinen et al., “MiR-34a expression has an effect for lower risk of metastasis and associates with expression patterns predicting clinical outcome in breast cancer,” PLoS ONE, vol. 6, no. 11, Article ID e26122, 2011. View at Publisher · View at Google Scholar · View at Scopus
  154. J. Silber, D. A. Lim, C. Petritsch et al., “miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells,” BMC Medicine, vol. 6, no. 1, article 14, 2008. View at Publisher · View at Google Scholar · View at Scopus
  155. A. Bier, N. Giladi, N. Kronfeld et al., “MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1,” Oncotarget, vol. 4, no. 5, pp. 665–676, 2013. View at Publisher · View at Google Scholar · View at Scopus
  156. G. Sun, Y. Cao, L. Shi et al., “Overexpressed miRNA-137 inhibits human glioma cells growth by targeting Rac1,” Cancer Biotherapy and Radiopharmaceuticals, vol. 28, no. 4, pp. 327–334, 2013. View at Publisher · View at Google Scholar · View at Scopus
  157. L. Chen, X. Wang, H. Wang et al., “miR-137 is frequently down-regulated in glioblastoma and is a negative regulator of Cox-2,” European Journal of Cancer, vol. 48, no. 16, pp. 3104–3111, 2012. View at Publisher · View at Google Scholar · View at Scopus
  158. J. Sun, G. Zheng, Z. Gu, and Z. Guo, “MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2,” Journal of Neuro-Oncology, vol. 122, no. 3, pp. 481–489, 2015. View at Publisher · View at Google Scholar · View at Scopus
  159. Y. Sun, X. Zhao, Y. Zhou, and Y. Hu, “MiR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect,” Oncology Reports, vol. 28, no. 4, pp. 1346–1352, 2012. View at Publisher · View at Google Scholar · View at Scopus
  160. B. Chen, Y. Liu, X. Jin et al., “MicroRNA-26a regulates glucose metabolism by direct targeting PDHX in colorectal cancer cells,” BMC Cancer, vol. 14, no. 1, article no. 443, 2014. View at Publisher · View at Google Scholar · View at Scopus
  161. T. Yamasaki, N. Seki, H. Yoshino et al., “Tumor-suppressive microRNA-1291 directly regulates glucose transporter 1 in renal cell carcinoma,” Cancer Science, vol. 104, no. 11, pp. 1411–1419, 2013. View at Publisher · View at Google Scholar · View at Scopus
  162. X. Fei, M. Qi, B. Wu, Y. Song, Y. Wang, and T. Li, “MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression,” FEBS Letters, vol. 586, no. 4, pp. 392–397, 2012. View at Publisher · View at Google Scholar · View at Scopus
  163. Q.-Q. Zhang, H. Xu, M.-B. Huang et al., “MicroRNA-195 plays a tumor-suppressor role in human glioblastoma cells by targeting signaling pathways involved in cellular proliferation and invasion,” Neuro-Oncology, vol. 14, no. 3, pp. 278–287, 2012. View at Publisher · View at Google Scholar · View at Scopus
  164. L. Chang, X. Lei, Y. Qin et al., “MicroRNA-133b inhibits cell migration and invasion by targeting matrix metalloproteinase 14 in glioblastoma,” Oncology Letters, vol. 10, no. 5, pp. 2781–2786, 2015. View at Publisher · View at Google Scholar · View at Scopus
  165. T.-S. Wong, X.-B. Liu, A. C.-W. Ho, A. P.-W. Yuen, R. W.-M. Ng, and W. I. Wei, “Identification of pyruvate kinase type M2 as potential oncoprotein in squamous cell carcinoma of tongue through microRNA profiling,” International Journal of Cancer, vol. 123, no. 2, pp. 251–257, 2008. View at Publisher · View at Google Scholar · View at Scopus
  166. M. Sakr, T. Takino, H. Sabit, M. Nakada, Z. Li, and H. Sato, “MiR-150-5p and miR-133a suppress glioma cell proliferation and migration through targeting membrane-type-1 matrix metalloproteinase,” Gene, vol. 587, no. 2, pp. 155–162, 2016. View at Publisher · View at Google Scholar · View at Scopus
  167. A. M. Liu, Z. Xu, F. H. Shek et al., “MiR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma,” PLoS ONE, vol. 9, no. 1, Article ID e86872, 2014. View at Publisher · View at Google Scholar · View at Scopus
  168. G. Wang, Y. Zhao, and Y. Zheng, “miR-122/Wnt/β-catenin regulatory circuitry sustains glioma progression,” Tumor Biology, vol. 35, no. 9, pp. 8565–8572, 2014. View at Publisher · View at Google Scholar · View at Scopus
  169. K. K. W. Li, J. C. S. Pang, A. K. K. Ching et al., “miR-124 is frequently down-regulated in medulloblastoma and is a negative regulator of SLC16A1,” Human Pathology, vol. 40, no. 9, pp. 1234–1243, 2009. View at Publisher · View at Google Scholar · View at Scopus
  170. W. Li, H. Huang, J. Su et al., “miR-124 acts as a tumor suppressor in glioblastoma via the inhibition of signal transducer and activator of transcription 3,” Molecular Neurobiology, vol. 54, no. 4, pp. 2555–2561, 2017. View at Publisher · View at Google Scholar · View at Scopus
  171. J. Zhang, Y. Lu, X. Yue et al., “miR-124 suppresses growth of human colorectal cancer by inhibiting STAT3,” PLoS ONE, vol. 8, no. 8, Article ID e70300, 2013. View at Google Scholar
  172. Y. Cheng, Y. Li, Y. Nian, D. Liu, F. Dai, and J. Zhang, “STAT3 is involved in miR-124-mediated suppressive effects on esophageal cancer cells,” BMC Cancer, vol. 15, no. 1, article no. 306, 2015. View at Publisher · View at Google Scholar · View at Scopus
  173. H. Tang, M. Lee, O. Sharpe et al., “Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems,” FASEB Journal, vol. 26, no. 11, pp. 4710–4721, 2012. View at Publisher · View at Google Scholar · View at Scopus
  174. J.-Y. Sun, W.-Z. Xiao, F. Wang et al., “MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1,” Molecular Medicine Reports, vol. 12, no. 2, pp. 2355–2359, 2015. View at Publisher · View at Google Scholar · View at Scopus
  175. T. Kinoshita, N. Nohata, H. Yoshino et al., “Tumor suppressive microRNA-375 regulates lactate dehydrogenase B in maxillary sinus squamous cell carcinoma,” International Journal of Oncology, vol. 40, no. 1, pp. 185–193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  176. C. Chang, H. Shi, C. Wang et al., “Correlation of microRNA-375 downregulation with unfavorable clinical outcome of patients with glioma,” Neuroscience Letters, vol. 531, no. 2, pp. 204–208, 2012. View at Publisher · View at Google Scholar · View at Scopus
  177. Y. Isozaki, I. Hoshino, N. Nohata et al., “Identification of novel molecular targets regulated by tumor suppressive miR-375 induced by histone acetylation in esophageal squamous cell carcinoma,” International Journal of Oncology, vol. 41, no. 3, pp. 985–994, 2012. View at Publisher · View at Google Scholar · View at Scopus